Deals this week: Teva Pharmaceutical, Euroimmun AG, T2 Biosystems

21 July 2016 (Last Updated July 21st, 2016 18:30)

Teva Pharmaceutical Industries, through its financial arm Teva Pharmaceutical Finance Netherlands, has announced a public placement of 3.15% senior notes due 2026.

Teva Pharmaceutical Industries, through its financial arm Teva Pharmaceutical Finance Netherlands, has announced a public placement of 3.15% senior notes due 2026.

The gross proceeds of $3.5bn to be raised from the offering will be used by the company to finance its acquisition of Actavis Generics and for other general corporate purposes.

Concurrently, Teva Pharma has also announced a number of public offerings including the placement of 1.4% senior notes due 20 July 2018 to raise gross proceeds of $1.5bn, 1.7% senior notes due 19 July 2019 to raise gross proceeds of $2bn, 2.2% senior notes due 21 July 2021 to raise gross proceeds of $3bn, 2.8% senior notes due 21 July 2023 to raise gross proceeds of $3bn, and 4.1% senior notes due 1 October 2046 to raise gross proceeds of $2bn.

"The sensitivity of the platform in blood coagulation research allows for rapid and comprehensive monitoring of drug side effects in animal models and patients."

The company will receive aggregate net proceeds of approximately $14.9bn through the offerings.

Euroimmun AG and Iron Horse Diagnostics have signed a non-exclusive licensing agreement to launch the first biological diagnostic test for amyotrophic lateral sclerosis (ALS).

According to the agreement, the former will launch the product as a CE-marked product, while the latter will launch it in the US as a laboratory-developed test in CLIA-certified laboratories.

The agreement complements Euroimmun’s portfolio of neurological diagnostics and also enables it to develop new ALS diagnostic assay in collaboration with Iron Horse Diagnostics.

T2 Biosystems, a diagnostic products company, and Bayer AG have entered a multi-year research and development (R&D) agreement to drive drug monitoring and biomarker discovery for blood coagulation disorders.

As per the agreement, the T2 magnetic resonance technology platform (T2MR) of T2 Biosystems will be provided for Bayer’s research and development (R&D) efforts in blood coagulation disorders.

The sensitivity of the platform in blood coagulation research allows for rapid and comprehensive monitoring of drug side effects in animal models and patients.

The collaboration will further help the companies to develop tools and evaluate assays that aid in drug discovery and biomarker research for select Bayer haemostasis-related programmes.

Cloud-based solutions provider, Medidata Solutions, has collaborated with New York-based Memorial Sloan Kettering Cancer Center (MSK) to expand the use of mobile health (mHealth) technology in oncology care.

Through the collaboration, the two parties will assess the possibility of using wearable sensors such as activity trackers and mobile technology such as mobile apps and Medidata’s cloud technology platform to evaluate the quality of life during cancer treatment.

They will study the patterns of movement in patients receiving treatment for multiple myeloma.

Indivumed GmbH and Definiens AG have announced a strategic partnership to deploy tumour tissue for drug discovery and development.

Pursuant to the terms of the agreement, Definiens, a pioneer in Tissue Phenomics solutions for diagnostics development, along with its partner, will offer their customers a unique combination of tissue-based biomarker validation and assay development using its Cognition Network Technology for image analysis and data mining along with the latter’s cancer database, biobank, and analytical laboratory services for tissue analysis.